Ever since the invention of CRISPR technology about a decade ago, biologists have gained increasing power to discover new DNA sequences, cut and mash them up, and then print them in ever larger volumes through biomanufacturers. That freedom and openness is the opening to a long-awaited Century of Bio, with scientists bullish on the potential to discover cures to long-resistant diseases.

On the tails side of the coin though, there are fears that the open nature of these tools afford a rebel scientist the means of inventing and distributing well-known or completely novel pathogens that could threaten the lives of millions. It’s not the premise for a bad Hollywood B-movie, but a top security threat that experts at the White House and in the intelligence and defense communities are rapidly trying to solve.

Today, I have Kevin Flyangolts of Aclid joining us. Aclid is using artificial intelligence to identify what new sequences of DNA might do, scaling up screening efforts that might allow biomanufacturers the ability to verify their customers’ intentions in a more thoughtful and comprehensive way.

Kevin and host Danny Crichton talk about the recent history of bio, the rise of biohacking, the differences between bioweapons, cyberweapons and financial crimes, why we need new approaches to biosecurity, whether executive, legislative or industry approaches might work best, and whether designer bioweapons are as dangerous as many are making them out to be.
Finally, a note: in line with the launch of our first riskgaming scenario on the Lux Capital website, Hampton at the Cross-Roads, we have officially condensed the “Securities” podcast name into just “Riskgaming,” which I think captures in one word the risks and opportunities that come from science, technology, finance and the human condition. Same show, more focused name and a great future.